The Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinemia suggests that prolactin levels over 50 ng/ml or with clinical symptoms require the adaptation of antipsychotic medication (lowering doses, changing the antipsychotic, adding substances known to decrease prolactin levels such as aripiprazole). This evidence concerns the gene PRL and hyperprolactinemia.